
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive...
HypertensionPractical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With...
GlaucomaOcular HypertensionNon-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions. Data were entered into an electronic case report form.

Hemodynamics, Salt Sensitivity and Body Composition in Patients With Morbid Obesity
ObesityHypertensionThe purpose of this study is to evaluate the effect of high vs. low sodium intake on blood pressure and system hemodynamics in patients with morbid obesity and to evaluate the impact of laparoscopic gastric bypass on blood pressure, salt sensitivity and body composition in morbidly obese patients. Furthermore, we wants to describe the hemodynamic mechanisms involved in the amelioration of blood pressure during long-term weight loss.

Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
HypertensionThe efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study
High Blood PressureThe objective of this protocol is to improve awareness, treatment, and control of arterial hypertension, within primary prevention of target organ damage, by implementing guidelines, after training of the participating physicians.

Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated...
Glaucoma,Open-AngleOcular HypertensionThe primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months

Analysis of Genes That Predispose People to Develop High Blood Pressure
HypertensionHigh blood pressure affects nearly one third of all individuals in the United States. It is believed that genetic factors may predispose some people to develop this disease. This study will identify and characterize variations in three genes known to play a part in the development of high blood pressure.

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
GlaucomaPulmonary HypertensionThere is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a disease characterized by low oxygen levels in the blood and altered blood circulation. The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(NFL)in the retina and the resulting visual field compromise. This situation is characteristic of glaucoma. The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss. We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension...
Open-Angle GlaucomaOcular HypertensionTo investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension

Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?
HypertensionDialysis1 moreIt is well known that Aldosterone (aldo) can cause hypertension (HBP). Since aldo is known to cause the kidney to retain sodium (Na) and Na retention is known to cause HBP, it has been thought that the mechanism by which aldo causes HBP is by Na retention. Recent studies have suggested that aldo has many effects in addition to its ability to cause the kidney to retain Na. To test the hypothesis that aldo can cause HBP in a manner which does not involve Na retention, we plan, in this protocol, to give Eplerenone, a specific aldo antagonist, to patients on dialysis who have HBP. A positive effect of Eplerenone to lower HBP in these patients would support this hypothesis.